<b><i>PTEN</i></b> deletion and heme oxygenase‐1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome
Yunru Li(University of Calgary), Tarek A. Bismar(University of Calgary), Krikor Bijian(Jewish General Hospital), Maisa Yoshimoto(University of Alberta), Jianguo Zhang(Academy of Medical Sciences), Jie Su(Fujian Medical University), Shuhong Liu(Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences), Jeremy A. Squire(Universidade de São Paulo), Ajay Gupta(McGill University), Moulay A Alaoui Jamali(Jewish General Hospital)
Cited by 69
Related Papers
FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome
|British Journal of Cancer|2007|294
Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome
|Modern Pathology|2008|278
<i>PTEN</i> genomic deletion is associated with p‐Akt and AR signalling in poorer outcome, hormone refractory prostate cancer
|The Journal of Pathology|2009|210
Three-Color FISH Analysis of TMPRSS2/ERG Fusions in Prostate Cancer Indicates That Genomic Microdeletion of Chromosome 21 Is Associated with Rearrangement
|Neoplasia|2006|186
Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis
|Proceedings of the National Academy of Sciences|2008|182